Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients. By selectively inhibiting L-type calcium channels in vascular smooth muscle, it promotes arterial vasodilation and reduces systemic vascular resistance. GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Lercanidipine is used to treat hypertension, a condition characterized by elevated arterial blood pressure. - Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. - Isolated systolic hypertension: provides arterial vasodilation to control high systolic readings. - Secondary hypertension: assists in managing blood pressure when caused by other underlying conditions. - Hypertension in elderly patients: offers once‑daily dosing to improve adherence.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema

Serious or Rare Side Effects: - Severe hypotension - Hepatic dysfunction - Angioedema

When prescribing Lercanidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution and consider dose adjustment in patients with liver dysfunction. - Elderly patients: start with the lowest effective dose due to increased sensitivity. - Concomitant beta‑blockers: monitor for additive heart rate effects. - Pregnancy and lactation: avoid unless benefits outweigh risks, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Lercanidipine can interact with other medicines, influencing its antihypertensive effect or increasing adverse reaction risk.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations, increasing toxicity risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels. - Grapefruit juice: can elevate Lercanidipine exposure, leading to enhanced hypotensive effect.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure lowering. - Simvastatin: increased risk of statin‑related muscle toxicity due to shared metabolism.